Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sanchita Porwal"'
Autor:
Jörn M. Schattenberg, Maria-Magdalena Balp, Brenda Reinhart, Sanchita Porwal, Andreas Tietz, Marcos C. Pedrosa, Matt Docherty
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 1, Pp 101-108 (2024)
Background and Aims: There is a high unmet need to develop noninvasive tools to identify nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients at risk of fast progression to end-stage liver disease (ESLD). This study des
Externí odkaz:
https://doaj.org/article/8a45e763c2394b37b5a87700e9f313ed
Autor:
Brenda Reinhart, Matt Docherty, Maria Magdalena Balp, Stephane Régnier, Andreas Tietz, Jennifer Cai, Sanchita Porwal, Marcos Pedrosa, Jörn M. Schattenberg
Publikováno v:
Journal of Hepatology. 73:S403-S404
Autor:
Thomas S. Marshall, Kushan Thakkar, Joanna C Huang, Sanchita Porwal, Tanja Rosenberg, Sudeep Karve
Publikováno v:
Blood. 132:3537-3537
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) remain mainstay in the management of patients with CML. Several TKIs have been approved over the last two decades. Even though efficacy and safety remain as the primary drivers in treatment selection, i
Autor:
Shaum M Kabadi, John M. Pagel, Joanna C Huang, Vinjamuri Sai Sudhir, Krish Patel, Sanchita Porwal, Kushan Thakkar
Publikováno v:
Blood. 132:3534-3534
Existing studies evaluating patient adherence to oral targeted therapies such as tyrosine kinase inhibitors focus on small populations with single malignancies. This study evaluated patterns of use of oral agents in a larger population across multipl
Publikováno v:
Blood. 132:3585-3585
INTRODUCTION: Chronic myeloid leukemia (CML), a myeloproliferative neoplasm is primarily treated using tyrosine kinase inhibitors (TKIs). Several next-generation TKIs (dasatinib, nilotinib, bosutinib, ponatinib) have been approved since the first app